Arginine AKG (AAKG).

Citrulline is converted to arginine in the kidney and bypasses the intestinal arginase that degrades a large share of oral arginine. Pairing them raises and then sustains the same plasma arginine pool.

Lysine and arginine both cross membranes on the y+ cationic amino acid transporters, so a large lysine dose competes directly with arginine uptake. Formulas carrying both should know they contend for one carrier.

Arginase cleaves arginine into ornithine and urea, so ornithine is the direct downstream product and the entry point back into the cycle. Together they support normal ammonia handling from both ends.

Alpha-ketoglutarate accepts an amino group to become glutamate and then glutamine, which is how the body carries nitrogen between tissues. The AKG half of this salt feeds directly into that route.

Prolyl and lysyl hydroxylases use alpha-ketoglutarate as co-substrate and ascorbate to keep their iron centre reduced, so the two work in one reaction during collagen assembly. Ascorbate separately protects the tetrahydrobiopterin that nitric oxide synthase needs for the arginine half.

Alpha-ketoglutarate dependent dioxygenases, including the collagen hydroxylases, carry a ferrous iron centre in the active site. Iron status therefore governs whether the AKG half can be used in those reactions.

Arginine donates its amidino group to glycine through AGAT to form guanidinoacetate, the committed step toward creatine. The two amino acids are co-substrates in one reaction.

Dietary nitrate is reduced to nitric oxide without an enzyme substrate, while arginine works through nitric oxide synthase. The routes cover different oxygen conditions and do not compete.

Pine bark polyphenols support endothelial nitric oxide synthase activity and limit oxidative loss of its product. Arginine is the substrate that enzyme consumes.

Norvaline inhibits arginase, the enzyme that diverts arginine to ornithine and urea. Slowing that diversion leaves more arginine for nitric oxide synthase.

Alpha ketoglutarate is the standard amino group acceptor in transamination, and every aminotransferase that hands a group to it requires pyridoxal 5 phosphate. Vitamin B6 status therefore sits directly on the pathway that consumes the AKG half of this salt. That is cofactor biochemistry, not an added performance effect.

Nitric oxide synthase is a flavoprotein: electrons pass through FAD and FMN before reaching the heme, and both flavins come from dietary riboflavin. Arginine is the substrate of that enzyme, so riboflavin status is part of the machinery converting it. The relationship is structural biochemistry rather than a tested combination.

Nitric oxide synthase draws its electrons from NADPH, which the cell builds from niacin derived nicotinamide nucleotides. Arginine supply means little if the reducing equivalents are not there. This is a cofactor dependency in the pathway, not a claim about what the pair does in a person.

Arginine donates its amidino group to glycine to form guanidinoacetate, which is then methylated to creatine. Supplemental creatine bypasses that synthesis entirely and spares arginine for other routes. The two sit at opposite ends of one pathway, which is why they appear together in the same products.

Guanidinoacetate, formed from arginine, must be methylated by S-adenosylmethionine to become creatine, and that step is one of the largest methyl group demands in the body. Betaine supports methionine regeneration and therefore methyl availability. The link is pathway level; it does not by itself say anything about performance.

Nitric oxide synthase needs tetrahydrobiopterin to stay coupled, and folate species participate in regenerating that cofactor from its oxidised form. When the cofactor runs short the enzyme produces superoxide instead of nitric oxide, so arginine supply is not the only limiting factor. The biochemistry is described; whether folate status changes the response to an arginine dose has not been established.

Nitric oxide is consumed rapidly by superoxide, so the redox environment sets how much of it survives to act. NAC supports cysteine and glutathione availability, which is one part of that environment. This is a mechanistic argument for pairing rather than a demonstrated combination effect, so it stays at Promising.

Taurine is a cell osmolyte with described effects on endothelial and calcium handling, and it is a common co-ingredient with arginine salts in pre-exercise products. No combination trial grounds the pairing, so the row is Early and reflects co-formulation logic. Presence together in a product is not evidence of a joint effect.

Magnesium influences vascular smooth muscle calcium handling and is required by the many ATP dependent steps around nitric oxide signalling. That places it in the same physiological neighbourhood as arginine without establishing a joint effect. Early confidence is the honest label.

Arginine crosses membranes through cationic amino acid transporters that also carry other basic amino acids, so a large simultaneous dose of a competing substrate can slow its uptake. Histidine shares part of that handling. The competition is real at the transporter level; how much it matters at supplement doses has not been quantified.

A whey dose floods the same amino acid transport systems arginine uses, so a fasted arginine dose and a protein shake taken together do not behave like the dose alone. Whey also supplies arginine as part of its own amino acid profile, so the total intake is higher than the arginine label states. Spacing the two is the practical answer.

Arginine alpha ketoglutarate and caffeine appear together in most pre-exercise blends, where caffeine is the ingredient carrying the perceived effect. There is no established biochemical interaction between them, so this row records the co-formulation and nothing more. Attributing a blend result to the arginine salt is a common misreading.